Skip to main content
SpringerLink
Log in

Treatments for Improving Survival of Patients with Prostate Cancer

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Prostate cancer is a heterogeneous disease characterised by a long natural history relative to other solid tumours. With the diagnosis of prostate cancer being made earlier, the emphasis of treatment has shifted from palliation of symptoms to altering disease-related morbidity and mortality and thus improving overall survival.

Treatment of prostate cancer increasingly involves an approach that combines local therapies directed at the primary tumour together with systemic therapies to potentiate their effect and to control subclinical metastatic disease. Patients with localised tumours who are at high risk of relapsing with radiation therapy alone are surviving longer because of the addition of adjuvant hormonal therapy. Although a survival benefit in similar patients undergoing prostatectomy has not yet been established, preliminary results indicate that adjuvant hormonal therapy delays relapse.

Chemotherapy is an effective palliative modality for patients with hormone-refractory metastatic disease, and recently completed phase III trials will determine if chemotherapy can prolong survival for this group. The role of chemotherapy in patients with locally advanced tumours is also being investigated in randomised clinical trials.

Because bone is the dominant site of metastases for most patients with prostate cancer, the development of therapies that can slow tumour growth specifically within bone is a logical strategy. Bisphosphonates and bone-targeted radionuclides are two such approaches that have shown encouraging results even in the most advanced stages of the disease.

Although one can now reasonably hypothesise that survival has improved because of recent therapeutic advances, it remains to be conclusively established that cytotoxic or other systemic therapy can extend survival of patients with prostate cancer. Only the results of ongoing randomised trials can definitely establish that more patients with locally advanced and metastatic prostate cancer are living longer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics 2002. CA Cancer J Clin 2002; 52: 23–47

    Article  PubMed  Google Scholar 

  2. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591–7

    Article  PubMed  CAS  Google Scholar 

  3. Hussain MH, Crawford ED. Androgen deprivation strategies for metastatic prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, editors. Principles and practice of genitourinary oncology. Philadelphia (PA): Lippincott-Raven, 1996: 591

    Google Scholar 

  4. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag, 2002

    Google Scholar 

  5. Veterans Administration Cooperative Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Tennenbaum M, editor. Urologic oncology: the prostate. Philadelphia (PA): Lea and Fibiger, 1977: 171–4

    Google Scholar 

  6. Partin AW, Kattan MW, Subong ENP, et al. Combination of PSA, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997 May 14; 277(18): 1445–51

    Article  PubMed  CAS  Google Scholar 

  7. D’Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166(6): 2185–8

    Article  PubMed  Google Scholar 

  8. Smith DS, Catalona WJ. The nature of prostate cancer detected through PSA based screening. J Urol 1994 Nov; 152 (5 pt 2): 1732–6

    PubMed  CAS  Google Scholar 

  9. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–8

    Article  PubMed  CAS  Google Scholar 

  10. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer: multi-institutional pooled analysis. JAMA 1996 Aug 28; 276(8): 615–9

    Article  PubMed  CAS  Google Scholar 

  11. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002 Aug 15; 20(16): 3376–85

    Article  PubMed  Google Scholar 

  12. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002 Jul 15; 95(2): 281–6

    Article  PubMed  Google Scholar 

  13. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281(17): 1598–604

    Article  PubMed  CAS  Google Scholar 

  14. Hanks GE, Hanlon AL. Dose escalation with 3D conformai treatment: five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 1998; 41(3): 501–10

    Article  PubMed  CAS  Google Scholar 

  15. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson Phase III Randomized Trial. Int J Radiat Oncol Biol Phys 2002; 53(5): 1097–105

    Article  PubMed  Google Scholar 

  16. Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high dose three dimensional conformai radiotherapy. Cancer J Sci Am 1999; 5(3): 152–8

    PubMed  CAS  Google Scholar 

  17. Pollack A, Zagars GK, Rosen II. Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol 1999; 26(2): 150–61

    PubMed  CAS  Google Scholar 

  18. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112–6

    Article  PubMed  Google Scholar 

  19. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001 Aug; 50(5): 1243–52

    Article  PubMed  CAS  Google Scholar 

  20. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol 1997; 15: 1013–21

    PubMed  CAS  Google Scholar 

  21. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337(5): 295–300

    Article  PubMed  CAS  Google Scholar 

  22. Hanks GE, Lu J, Machtay M, et al. RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate [abstract 1284]. Proc Am Soc Clin Oncol 2000 May 20–23; 19: 327a

    Google Scholar 

  23. Zincke H, Bergstralh EJ, Larson-Keller JJ, et al. Stage Dl prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992; 70(1 Suppl.): 311–23

    Article  PubMed  CAS  Google Scholar 

  24. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 1781–8

    Article  PubMed  CAS  Google Scholar 

  25. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2001; 168(2): 429–35

    Article  Google Scholar 

  26. Zagars GK, Pollack A. Kinetics of Serum PSA after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44(3): 213–21

    Article  PubMed  CAS  Google Scholar 

  27. Huggins C, Hodges CV. Studies on prostatic cancer I: the effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7

    CAS  Google Scholar 

  28. Mcleod D, Zinner N, Gleason D, et al. Abarelix-depot vs leuprolide acetate for prostate cancer: results of multi-institutional, randomized, phase III study in 271 patients [abstract 1306]. Proc Am Soc Clin Oncol 2000 May 20–23; 19: 332a

    Google Scholar 

  29. Laufer M, Denmeade SR, Sinabaldi VJ, et al. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000; 164(1): 3–9

    Article  PubMed  CAS  Google Scholar 

  30. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–42

    Article  PubMed  CAS  Google Scholar 

  31. Crook JM, Szumacher E, Malone S, et al. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53(3): 530–4

    Article  PubMed  CAS  Google Scholar 

  32. Small EJ, Vogelzang NJ. Second line hormonal treatment for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15(1): 382–8

    PubMed  CAS  Google Scholar 

  33. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995; 76(8): 1428–34

    Article  PubMed  CAS  Google Scholar 

  34. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607–9

    PubMed  CAS  Google Scholar 

  35. Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group Study (SWOG 9235). Urology 2001 Jul; 58(1): 53–8

    Article  PubMed  CAS  Google Scholar 

  36. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001 Jan 1; 19(1): 62–71

    PubMed  CAS  Google Scholar 

  37. Nishimura K, Nonomura N, Yasunaga Y, et al. Low doses of oral dexamethasone for hormone-refractory prostate cancer. Cancer 2000 Dec 15; 89: 2570–6

    Article  PubMed  CAS  Google Scholar 

  38. Small EJ, Halabi S, Picus J, et al. A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high dose ketoconazole in androgen independent prostate cancer patients: results of CALGB 9583 [abstract 695]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a

    Google Scholar 

  39. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000 Feb 15; 88(4): 825–34

    Article  PubMed  CAS  Google Scholar 

  40. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000 Nov 11; 18(21): 3595–603

    PubMed  CAS  Google Scholar 

  41. Scher HI, Libertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural vs treated history of disease. J Clin Oncol 1997; 15: 2928–38

    PubMed  CAS  Google Scholar 

  42. Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone + prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14(6): 1756–64

    PubMed  CAS  Google Scholar 

  43. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999; 17: 2506–13

    PubMed  CAS  Google Scholar 

  44. Tew KD, Glusker JP, Hartley-Asp, et al. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther 1992; 56(3): 323–39

    Article  PubMed  CAS  Google Scholar 

  45. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15(30): 525–45

    Article  PubMed  CAS  Google Scholar 

  46. Hudes G, Einhorn L, Ross E, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network Phase III Trial. J Clin Oncol 1999; 17: 3160–6

    PubMed  CAS  Google Scholar 

  47. Hudes G, Ross E, Roth B, et al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate [abstract 704]. Proc Am Soc Clin Oncol 2002 May 18–21; 21: 177a

    Google Scholar 

  48. Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997 Sep; 15(9): 3156–63

    PubMed  CAS  Google Scholar 

  49. Hudes GR, Manola J, Conroy T, et al. Phase II study of weekly paclitaxel by 1 - hour infusion plus reduced-dose oral estramustine in metastatic hormone-refractory prostate carcinoma: a trial of the Eastern Cooperative Oncology Group[abstract 697]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 175a

    Google Scholar 

  50. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001 May 1; 19(9): 2509–16

    PubMed  CAS  Google Scholar 

  51. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001 Jan 1; 19(1): 44–53

    PubMed  CAS  Google Scholar 

  52. Smith DC, Esper P, Strawderman M, et al. Phase II trial of oral estramustine, oral etoposide and IV paclitaxel in hormone refractory prostate cancer. J Clin Oncol 1999; 17: 1664–71

    PubMed  CAS  Google Scholar 

  53. Hudes G. Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs 2002; 20(2): 159–72

    Article  PubMed  CAS  Google Scholar 

  54. Nelson JB, Carducci MA, Padley RJ, et al. The Endothelin-A receptor antagonist Atrasentan (ABT-627) reduces skeletal remodeling activity in men with advanced, hormone refractory prostate cancer [abstract 12]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 4a

    Google Scholar 

  55. Carducci MA, Nelson JB, Padley RJ, et al. The Endothelin-A receptor antagonist ABT-627 delays clinical progression in hormone refractory prostate cancer: a multinational, randomized, double-blind, placebo controlled trial [abstract 694]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a

    Google Scholar 

  56. Scher HI, Sarkis A, Reuter V, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1(5): 545–50

    PubMed  CAS  Google Scholar 

  57. Herbst RS, Maddox A, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002 Sep 15; 20(18): 3815–25

    Article  PubMed  CAS  Google Scholar 

  58. Baselga J, Rischin M, Ranson H, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types. J Clin Oncol 2002 Nov 1; 19(21): 4292–302

    Article  Google Scholar 

  59. Hildalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267–79

    Google Scholar 

  60. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 12: 4885–92

    Google Scholar 

  61. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59: 803–6

    PubMed  CAS  Google Scholar 

  62. Mark HFL, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66: 170–8

    Article  PubMed  CAS  Google Scholar 

  63. Kallakury BVS, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16: 1302–9

    PubMed  CAS  Google Scholar 

  64. Ye D, Mendelsohn J, Fan Z, et al. Androgen and epidermal growth factor down- regulate cyclin-dependent kinase inhibitor p27Kipl and co-stimulate proliferation of MDA Prostate cancer 2a and MDA Prostate cancer 2b prostate cancer cells. Clin Cancer Res 1999; 5: 2171–7

    PubMed  CAS  Google Scholar 

  65. Yang X, Jia X, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without chemotherapy. Cancer Res 1999; 59: 1236–43

    PubMed  CAS  Google Scholar 

  66. Ko Y-J, Small EJ, Kabbinavar F, et al. A multi-institutional Phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 800–5

    PubMed  CAS  Google Scholar 

  67. Uehara H, Kim SJ, Karashima T, et al. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice [abstract 2192]. Proc Am Assoc Cancer Res 2001; 42: 18

    Google Scholar 

  68. Bander NH, Trabulski EJ, Yao D, et al. Phase I radioimmunotherapy trials of humanized monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen (PSMAext) radiolabeled with 90yttrium or 177lutetium in advanced prostate cancer [abstract 18]. Proc Am Soc Clin Oncol 2002; 21: 5a

    Google Scholar 

  69. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894–903

    PubMed  CAS  Google Scholar 

  70. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6(15): 1632–8

    PubMed  CAS  Google Scholar 

  71. Simons J, Nelson W, Nemunaitis J, et al. Phase II trials of a GMCSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer [abstract 729]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 183a

    Google Scholar 

  72. Slovin S, Ragupathi G, Fernandez C, et al. A bivalent vaccine containing glycosylated MUC-2-KLH and globo H-KLH-conjugates using a new semi-synthetic saponin immunological adjuvant GP1-0100, in biochemically relapsed prostate cancer [abstract 781]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 196a

    Google Scholar 

  73. Kaufman HL, Wang W, et al. Prime/boost vaccination using poxviruses expressing PSA in D0 prostate cancer: preliminary results of ECOG 7897, a randomized phase II clinical trial [abstract 12]. Proc Am Soc Clin Oncol 2001 May 18–21; 21: 196a

    Google Scholar 

  74. Urwin GH, Percival RC, Harris S, et al. Generalized increase in bone resorption in carcinoma of the prostate. Br J Urol 1985 Dec; 57(6): 721–3

    Article  PubMed  CAS  Google Scholar 

  75. Rodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001 Aug 1; 19: 3562–71

    Google Scholar 

  76. Dougherty KM, Blomme EAG, Koh AJ, et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res 1999 Dec 1; 59: 6015–22

    PubMed  CAS  Google Scholar 

  77. Bryden AA, Hoyland JA, Freemont AJ, et al. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002 Feb 1;86(3): 322–5

    Article  PubMed  CAS  Google Scholar 

  78. Okamoto M, Lee C, Oyasu R, et al. Interleukin-6 as a paracrine and autocrine growth factor in prostatic carcinoma cells in vitro. Cancer Res 1997 Jan 1; 57(1): 141–6

    PubMed  CAS  Google Scholar 

  79. Nakashima J, Tachibana M, Horiguchi Y, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000 Jul; 6(7): 2702–6

    PubMed  CAS  Google Scholar 

  80. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000 Mar 1; 88(5): 1092–0

    Article  Google Scholar 

  81. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 1998 Feb; 16(2): 593–602

    PubMed  CAS  Google Scholar 

  82. Dearnaley DP, Sydes MR. Preliminary evidence that oral Clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PrO5 Trial [abstract 693]. Proc Am Soc Clin Oncol 2001 May 12–15; 20: 174a

    Google Scholar 

  83. Data on file, Novartis, Basal, 2003

  84. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 Sep 27; 345(13): 948–55

    Article  PubMed  CAS  Google Scholar 

  85. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001 Sep 15; 92(6): 1444–50

    Article  PubMed  CAS  Google Scholar 

  86. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994 Apr; 31(1): 33–40

    Article  PubMed  CAS  Google Scholar 

  87. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant, metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993 Apr 2; 25(5): 805–13

    Article  PubMed  CAS  Google Scholar 

  88. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind, placebo-controlled clinical trial. J Clin Oncol 1998 Apr; 16(4): 1574–81

    PubMed  CAS  Google Scholar 

  89. Tu S-M, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001 Feb 3; 357(9253): 336–41

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania, 19111, USA

    Alice K. David, Radhika Khwaja &  Gary R. Hudes

Authors
  1. Alice K. David
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Radhika Khwaja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary R. Hudes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary R. Hudes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

David, A.K., Khwaja, R. & Hudes, G.R. Treatments for Improving Survival of Patients with Prostate Cancer. Drugs Aging 20, 683–699 (2003). https://doi.org/10.2165/00002512-200320090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320090-00005

Keywords

Search

Navigation